1 citations
,
December 2021 in “Journal of Cosmetic Dermatology” This study observed that COVID-19 is associated with accelerated androgenetic alopecia, and platelet-rich plasma treatment showed improvement in hair loss after infection.
3 citations
,
December 2021 in “Journal of Cosmetic Dermatology” This study found no correlation between the severity of androgenetic alopecia and the severity of COVID-19 in hospitalized patients, contrary to some previous research.
3 citations
,
November 2020 in “Journal of The American Academy of Dermatology” This paper discusses the proposal that androgenetic alopecia, as seen in the "Gabrin sign", could indicate higher risk of severe COVID-19 symptoms, but its validity is questioned and further confirmation is needed.
November 2020 in “Journal of The American Academy of Dermatology” This article comments on previous studies linking severe androgenetic alopecia to increased vulnerability to COVID-19 and highlights ongoing research into antiandrogen therapies as potential treatments.
121 citations
,
November 2020 in “Endocrine” This review discusses evidence on androgen sensitivity as a potential factor in COVID-19 disease severity, suggesting that androgen receptor interactions could influence virus entry and progression, and reports no new clinical results.
119 citations
,
May 2020 in “Journal of The American Academy of Dermatology” This study observed a high prevalence of androgenetic alopecia in patients hospitalized with severe COVID-19, with 79% of men and 42% of women affected, suggesting a potential link between androgen sensitivity and COVID-19 severity.
123 citations
,
May 2020 in “Drug Development Research” This article argues that androgen sensitivity could be a key factor in the severity of COVID-19, suggesting that trials with anti-androgen agents may be warranted.
134 citations
,
April 2020 in “Journal of Cosmetic Dermatology” Male pattern hair loss could hint at androgens affecting COVID-19 severity.
